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tp://dx.doi.org/10.1016/j.hjc.2016
09-9666/ª 2016 Hellenic Cardiologi
ense (http://creativecommons.org/A polymorphic variant of the human a2B-adrenergic recep-
tor, which comprises the deletion of three glutamic acids
(Del301-303) in the third intracellular loop, has been found
to be common in Caucasians (31%) and less frequent in
African-Americans (12%).1,2 The deletion occurs within a
stretch of acidic residues that are essential for agonist-
promoted receptor phosphorylation by G protein-coupled
receptor kinases (GRKs), and its subsequent desensitiza-
tion by the recruitment of b-arrestins at the plasma mem-
brane.3 The Del301-303 variant of the a2B-adrenergic
receptor consistently exhibits decreased GRK-mediated
receptor phosphorylation and impaired desensitization in
comparison to the wild-type receptor.2 Clinical genetic
studies have previously revealed an association between
the deleted variant receptor and cardiovascular pathol-
ogies, including acute coronary events, hypertension and
sudden cardiac death, among others.1,4,5 In the present
study, we employed clones of LLC-PK1 cells, stably
expressing after transfection the wild-type a2B-AR or its
deleted variant, and investigated the signaling pathways
associated with the wild-type or deleted variant of human
a2B-AR.
The expression vectors were derived from the pREP4
plasmid and contained hemagglutinin-tagged wild-type a2B-
AR (pREP HA-a2B-WT) or hemagglutinin-tagged Del301-303
a2B-AR variant (pREP HA-a2B-Del), which were gifts from Dr.y of Hellenic Cardiological
.05.009
cal Society. Publishing services by
licenses/by-nc-nd/4.0/).Mika Scheinin (University of Turku, Finland). Receptor
expression and subcellular distribution were determined as
depicted and described in Fig. 1. The receptor phosphory-
lation was measured using an anti-phospho-serine antibody
on immuno-precipitated material, and the propensity to
undergo desensitization was examined using the GTPgS
binding assay. Soluble proteins were analyzed by Western
blotting. Phospho-IKKa/b, b-arrestins, phospho-Erk, phos-
pho-Akt and Erk were, respectively detected with their
specific primary antibody and the corresponding horse-
radish peroxidase-conjugated secondary antisera. Antib-
arrestins rabbit polyclonal antibody (A1CT) was a gift from
Dr. Robert J. Lefkowitz (Duke University Medical Center,
Durham, NC).
The receptor densities were comparable in the two
clones: 2.4  0.4 pmoles/mg of protein in LLC-a2B-WT4,
and 2.1  0.2 pmoles/mg of protein in LLC-a2B-Del4. The
affinity of [3H]RX821002 for WT (KdZ 8.1  1.2 nM) was
not different from that for Del a2B-AR (KdZ 6.5  0.7 nM),
and the receptor density remained stable over at least 20
successive cell passages. Confocal microscopy examination
of HA immunofluorescent staining indicated that WT and
Del a2B-AR exhibited the same pattern of subcellular dis-
tribution (Fig. 1).
We found a significant decrease w50% of the extent of
receptor phosphorylation in LLC-a2B-Del4 compared with
LLC-a2B-WT4, following short-term exposure of the cells to
the a2-agonist UK14304 (not shown). [
35S]GTPgS binding on
membranes prepared from the two clones demonstrated a
partial loss of desensitization in the LLC-a2B-Del4 clone (not
shown), in agreement with previous observations in CHO
cells.
Furthermore, immunoblotting with the b-arrestin anti-
body indicated that the Del a2B-AR exhibited slower kinetics
of b-arrestin recruitment and more persistent coupling to
its cognate G-proteins (data not shown). Moreover, a
divergence in the type of b-arrestin recruited was observedElsevier B.V. This is an open access article under the CC BY-NC-ND
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Fig. 1 Expression of WT and Del a2B- adrenergic receptors in
LLC-PK1 cells. A. LLC-a2BAR-WT4 and LLC-a2BAR-Del4 clones
were cultured on glass coverslips. The cells were fixed, per-
meabilized and immunolabeled with mouse anti-HA antibody/
anti-mouse Cy3. The results were analyzed on a Zeiss laser
confocal microscope. B. Membranes prepared from LLC-a2BAR-
WT4 or LLC-a2BAR-Del4 cells were incubated in the presence of
various concentrations of [3H]RX821002, and the amount of
specifically bound radioligand was determined using 10 mM
phentolamine to estimate the non-specific binding. The data
presented are from a typical experiment. Computer-assisted
analysis of the results from this specific experiment indicated
that the Bmax and Kd values of [3H]RX821002 were, respec-
tively 1.98  0.26 pmol/mg of protein and 6.17  0.73 nM for
LLC-a2BAR-Del4 cells and 1.84  0.12 pmol/mg of protein and
4.46  0.51 nM for LLC-a2BAR-Del4 cells.
Fig. 2 Activation of NF-kB and phosphorylation of IKKa/b. A.
LLC-a2BAR-WT4 (open bars) or LLC-a2BAR-Del4 (dark bars) cells
were transfected with the p-NF-kB Luc construct. Thirty-six
hours post-transfection, the cells were placed in serum-free
culture medium and subsequently treated or not (basal) with
PMA (PMA) or with 10 mM UK14304 in the absence (UK) or the
presence of 30 mM PD98059 (PDþUK) or 50 mM LY 240092
(LYþUK) or 10 mM PP1 (PP1þUK). The cells were collected and
assayed for luciferase activity 6 hours after the beginning of
the treatment. Luciferase activity is expressed as the fold-
Letter to the Editor 293between WT and Del a2B-adrenergic receptors: whereas b-
arrestin 2 was preferentially recruited within the first mi-
nutes following exposure of LLC-a2B-WT4 to the UK14304
agonist, it was b-arrestin 1 that was finally engaged after a
long period of stimulation of LLC-a2B-Del4. The functional
consequences of this divergence are unknown; however,
because b-arrestins 1 and 2 play discrete roles,3 they may
result in a difference in the intensity and duration of re-
ceptor signaling.increase relative to basal. Data are the mean  S.E.M. from
three individual experiments B. Serum-deprived LLC-a2BAR-
WT4 (upper panel) or LLC-a2BAPDel4 (lower panel) were
treated or not (basal) with PMA or with 10 mM UK14304 in the
absence (UK) or the presence of 30 mM PD98059 (PDþUK) or
50 mM LY 240092 (LYþUK). Cell lysates were prepared in RIPA,
proteins were separated on SDS-PAGE and immunoblotted using
anti- phosphorylated IKKa/b. A representative blot from at
least three sets of experiments is shown. C. Densitometric
analysis was performed and the data are presented as the
mean  S.E.M. of three independent experiments.
294 Letter to the EditorBoth receptors caused a rapid and long-lasting increase
in the phosphorylation of Erk and Akt. Phosphorylation of
Erk was partially inhibited by MMP inhibitors, heparin, and
tyrphostin, and persisted upon EGFR desensitization, indi-
cating that it is triggered both by EGFR-dependent and
EGFR-independent mechanisms, as previously described for
other cell types.6,7 The effects of the a2-agonist are
strongly attenuated by prior treatment of the cells with the
inhibitor of MEK1/2 (PD98059) of PI3-K (LY240092) and of
Src (PP1) (data not shown).
A variety of GPCRs have now been shown to regulate
inflammation and cell survival processes by controlling the
activation of NF-kB.8 The GPCRs include receptors for
bradykinin, fMLP (N-formyl methionyl leucyl phenylala-
nine), lysophosphatidic acid, and dopamine, as well as the
a2-adrenergic receptors.
9 Therefore, the capacity of WT
and Del a2B-ARs to activate NF-kB was investigated by
measuring luciferase activity and by following IKKa/b
phosphorylation. Luciferase activity was measured in cell
extracts prepared from LLC-PK1 cells transiently trans-
fected with pNF-kB Luc plasmid,9 and then treated with
regulator substances in the presence or absence of in-
hibitors, using a Lumat LB 9501 luminometer (Berthold
Technologies, Bad Wildbad, Germany). As shown in
Fig. 2A, long-term exposure of LLC-PK1 cells to UK14304
markedly enhanced the activity of the pNF-kB Luc
construct regardless of the type of a2B-AR expressed. In
LLC-a2B-WT4, the effect of UK14304 was not affected by a
prior treatment with the MEK1 inhibitor PD98059, but was
completely abolished by prior treatment with the PI-3K
inhibitor, LY294002 (Fig. 2A). The situation was some-
what different in LLC-a2B-Del4, where the induction of
luciferase was inhibited to the same extent (55-60%
reduction) in the presence of these inhibitors. Fairly
similar findings were obtained with regard to the UK14304-
induced IKKa/b phosphorylation (Fig. 2B). UK14304 caused
IKKa/b phosphorylation and LY240092 inhibited IKKa/b
phosphorylation and NF-kB activation by WT or Del a2B-AR.
In contrast, PD98059 was efficient in cells expressing the
Del a2B-adrenergic receptor, but not the WT. The reasons
for the differences in the sensitivity of the NF-kB pathway
to inhibitors are difficult to understand, especially as we
did not find any evidence for the difference in the kinetics
and mechanisms of MAPK activation between the two re-
ceptors. Because b-arrestins 1 and 2 are both binding
partners of IkBa, the difference between WT and Del a2B-
adrenergic receptor may be the consequence of their
distinct capacity to recruit b-arrestins.
Overall, the present data have demonstrated great
similarities but also certain major differences between the
signaling pathways of the WT and Del a2B-AR in LLC-PK1
cells. Given the aforementioned associations of this
variant receptor with cardiovascular pathologies,1,4,5 the
differences and their molecular basis found in the present
study would merit confirmation in other cellular models
relevant to cardiovascular pathologies. Furthermore, these
post-receptor signaling differences add to the clinical
relevance of the variant receptor in other domains, such as
neurobiology and psychotherapy, based on the recentlyfound association of the polymorphic variant a2B- adren-
ergic receptor with differential amygdala activation and
emotional memory.10
Abbreviations
GPCR G-protein-coupled receptor
MMP matrix metalloproteinase
MEK mitogen-activated protein kinase kinase
PI-3K phosphoinisitide3-kinase
Bmax the maximal density of the receptor site in the
membrane preparation
Kd equilibrium dissociation constant
PMA phorbol myristate acetate
IKKa/b inhibitor of NF-kB kinase, subunits alpha & beta
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel
electrophoresis
PP1 Src family tyrosine kinase inhibitor
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